BRD-3308

BRD-3308 is a potent and highly selective small molecule inhibitor of Histone Deacetylase 3 (HDAC3), a class I HDAC. Developed by the Broad Institute, it is frequently utilized as a chemical probe to investigate the biological roles of HDAC3 in various disease states, including oncology and metabolic disorders. In the context of diffuse large B-cell lymphoma (DLBCL), particularly the BN2 subtype characterized by SPEN mutations, BRD-3308 has demonstrated the ability to sensitize lymphoma cells by targeting the BCL6-HDAC3 axis. Its selectivity for HDAC3 over other class I HDACs (HDAC1 and HDAC2) makes it a valuable tool for dissecting isoform-specific functions and a potential lead for therapeutic development in cancers and type 2 diabetes.